More Related Content Similar to India Healthcare Summit + Hackathon VIT-MIT-MGH zenchu031513 (20) India Healthcare Summit + Hackathon VIT-MIT-MGH zenchu0315131. WHY HACKING MEDICINE?
WHY NOW?
WHY INDIA?
ZEN CHU
MIT HEALTHCARE VENTURES
INNOVATOR CONCLAVE FOR MED TECH
VELLORE INSTITUTE OF TECHNOLOGY
CHRISTIAN MEDICAL COLLEGE
MASSACHUSETTS GENERAL HOSPITAL
MARCH 15, 2013
© ZEN CHU 2010
2. WHY NOW?
• HEALTHCARE CRISIS
• ALTRUISM INSUFFICIENT
• GLOBAL CLINICAL INNOVATION
• MACRO TECHNOLOGY TRENDS
• SUSTAINABLE VENTURES
• ENTREPRENEURS CRITICAL
© ZEN CHU 2010
3. WHY INDIA?
• UNIQUE NEEDS
• DEMOGRAPHICS
• NEW CLINICAL INNOVATION
• RACIAL/REGIONAL DIFFERENCES
• EMERGING MIDDLE CLASS
© ZEN CHU 2010
4. H@CKING MEDICINE
• CLEVER SOLUTIONS
• IDEAS ARE CHEAP
• PROVE OR FAIL FAST
• LEAN STARTUPS + DESIGN THINKING
• ACCELERATE DATA + PROOF
• ENTREPRENEURSHIP + MISSION
© ZEN CHU 2010
6. The birth of one of the first HackingMedicine venture-backed companies…
Amazing things happen in 36 hours!
8. Craig Lipset, Director of Clinical Innovation, Pfizer
Faster, Better, Cheaper Data Generation = Central to Pharma Productivity
9. Joe Smith, Chief Med Officer of West Health Institute & MIT/HST Alum
Demonstrating disconnect between health spending and quality outcomes
10. The Pitch as central vehicle to test & hone mission, solution, business model
16. MENTORS VS. EXPERTS
“The problem with experts is
that they do not know what
they do not know…
The problem is that we like to
have maps–and seem to prefer
to have the wrong map of
reality to no map at all.
~ Nassim Nicholas Taleb
The Black Swan
SURROUND TEAMS WITH MENTORS
PULL EXPERTS IN LATER, BUT START WITH NEEDS
© ZEN CHU 2010
18. HEALTHCARE METRICS
CONVENIENCE
CAPACITY
TRUST
BETTER
FASTER
CHEAPER
TRUST + WORKFLOW ESSENTIAL
© ZEN CHU 2010
19. HEALTHCARE FRAMEWORK
MONITORING
R
EFFECTIVE TREATMENTS
GE O
IA F
TR CH
DIAGNOSTICS
& TE
G &
IN S
PREVENTION
UT EM
RO ST
SY
EDUCATION
TECH ENABLES SCALABLE MEDICINE
© ZEN CHU 2010
20. WHICH RISKS TO PRIORITIZE?
TYPICAL ORDER OF UNIVERSITY SPIN-OUT
4
Market Risk
Payment
Physician & Patient Adoption
Packaged Whole Solutions
Value
3
Regulatory Risk
Safety & Efficacy
2
Management Risk
1
Technology IP Risk
© ZEN CHU 2010
Time
21. WHICH RISKS TO PRIORITIZE?
BEST ENTREPRENEURS + INVESTORS PRIORITIZE IN REVERSE
CHOOSE BASED
ON COST/PERFORMANCE
REQUIREMENTS
Technology IP Risk
Management Risk
Value
Regulatory Risk
Safety & Efficacy
Market Risk
Payment
Physician & Patient Adoption ATTACK FIRST!
Packaged Whole Solutions
© ZEN CHU 2010
Time
23. HACKATHON PROCESS
• START WITH PROBLEMS + JOBS TO DO
• EMPATHY FOR USER
• DIVERSE TEAMS AROUND THEMES
• LOTS OF WILD IDEAS
• DEFER JUDGEMENT
• BUILD ON IDEAS COLLABORATIVELY
• RAPID CLINICAL FEEDBACK
© ZEN CHU 2010
24. OPEN INNOVATION
• OPEN YOURSELVES TO CRAZY IDEAS
• OPEN UNIVERSITY TO INDUSTRY NEEDS
• SEEK DIVERSE TEAMS
• SEEK CRITICAL FEEDBACK EARLY
• DEFER PATENTING UNTIL LATER INSIGHTS
© ZEN CHU 2010
25. JUST THE BEGINNING
1st WEEKEND ACCELERATES PROCESS
• CHOOSE THE MISSION
• MAXIMIZE COLLISIONS
• MAXIMIZE FEEDBACK
• IDENTIFY CRITICAL EXPERIMENTS
H@CK PROTO DATA IP VENTURE
© ZEN CHU 2010
26. THANK YOU VIT + MGH!
IMAGINATION IS MORE IMPORTANT
THAN KNOWLEDGE
ALBERT EINSTEIN
HackingMedicine.MIT.edu
Twitter: #HackingMedicine @hackmedMIT
AboutMe.com/ZenVen
27. H@CK VIT - DAY 2
9 ORDER OF THE DAY
NEW CLINICIANS
10 JUDGING CRITERIA
11 BIG PIVOT PITCHES
MAD LIB PITCH
12 LUNCH
2 FIRST ROUND JUDGING - BREAKOUT ROOMS BY THEME
3 SEMI FINAL JUDGING - MAIN ROOM 412 GALLERY
4:30 JUDGES ANNOUNCE WINNERS
28. VALUE OF THE PITCH
• 56 PITCHES YESTERDAY!
• LIMIT TO 3 MINUTES + 2 MIN Q&A
• MISSION: WHY SHOULD ANYONE CARE?
• RAPID FEEDBACK
• FORCE CHANGE IN PROBLEM, SOLUTION, TEAM MIX
• ROLE-PLAY AS ENTREPRENEURS
• COMMUNICATE SOLUTION CONCISELY + ELOQUENTLY
• PROVE OR DIS-PROVE VALUE + APPROACH
© ZEN CHU 2010
29. PIVOT ON YOUR IDEA
• IDEAS GET CEMENTED IN OUR MINDS
• ESPECIALLY AROUND TECHNOLOGY ORIGIN
• SEEK JOBS THAT CANNOT BE DONE TODAY
• START WITH DESCRIBING THE USER EXPERIENCE
• NEW SERVICE, NEW LOCATION, FASTER, CONVENIENCE...
• GET RAPID FEEDBACK FROM INTENDED USERS
WHO LEARNED + PIVOTED?
© ZEN CHU 2010
30. SCALING MEDICINE
• CREATE NEW EXPERIENCE
• INCREASE CAPACITY
• NEW SERVICE / PROVIDER with CAPACITY
• CREATE NEW PLACE FOR SERVICE
• DE-SKILL COMPLEX DIAGNOSTIC / TREATMENT
• PATIENT SELF-SERVICE
© ZEN CHU 2010
31. WHAT IS NEW SERVICE
ENABLED BY YOUR TECH?
DESCRIBE THE
EXPERIENCE, EXPERIENCE, EXPERIENCE!
© ZEN CHU 2010
32. WHERE DOES SERVICE
TAKE PLACE?
TRAIN
STATION
PHARMACY
PATIENT
HOUSE
CLINIC
SCHOOL HOSPITAL
VILLAGE SPEC
IALIZ
CE ATIO
V E NIEN N
/
IN
CON F REQU
CITY ENCY
MUMBAI
BOSTON
© ZEN CHU 2010
33. FUNDING IS A CRUTCH
• CONSTRAINTS FORCE CREATIVITY
• SEEK JOBS THAT CANNOT BE DONE TODAY
• START WITH DESCRIBING THE USER EXPERIENCE
• NEW SERVICE, NEW LOCATION, FASTER, CONVENIENCE...
• GET RAPID FEEDBACK FROM INTENDED USERS
EXPERIMENT CHEAPLY + QUICKLY
© ZEN CHU 2010
34. JUDGING CRITERIA
5+ CASH AWARDS FOR HACKING VALUES
• PROBLEM STATEMENT CLEAR + BRIEF
• DETAILED USER EXPERIENCE DESCRIPTION
• PITCH + SHOWMANSHIP
• WOW FACTOR = UNIQUE SOLUTION
• MOST CLINICAL FEEDBACK
• GENERATED NEW DATA OVER WEEKEND
• PROTOTYPE EXPERIENCE (PAPER, DRAWINGS, ETC.)
• TEAM DIVERSITY
• GET OUT OF THE BUILDING TO TEST
• SUSTAINABLE ECONOMICS
• WEIGHT: 1/3 PUBLIC HEALTH 1/3 TECH 1/3 BIZ MODEL
© ZEN CHU 2010
35. MAD LIB PITCH TEMPLATE
• I AM A _____________________
• MY GOAL IS TO IMPROVE
• QUALITY OF _________ (CLINICAL METRIC, EXPERIENCE, PAIN…)
• ACCESS TO _________ (SERVICE, SKILL,
• FREQUENCY/RATE OF _________________ (TEST, BEHAVIOR, DX, SURG)
• EFFICIENCY OF _________________ (TEST, DX, EXPERIENCE, SURG…)
• PROFITS OF _____________________ (PHARMACY, DOC, HOSP, FIELD…)
• FIRST TARGET CUSTOMER IS _________ (DESCRIBE SUB-POPULATION)
• THEY SUFFER FROM _________ (DISEASE, EXPERIENCE, PAIN…)
• WE CAN IMPROVE THEIR EXPERIENCE/HEALTH BY _________
• TODAY THEY SOLVE THIS BY _________ BUT THE PROBLEM IS _________
• OUR SOLUTION IS TO ATTACK _________
• STARTING WITH _________ (FOCUSED POPULATION)
• THEY WILL BE EARLY ADOPTERS BECAUSE (HIGHER SUFFERING, PAIN, COST, RISK, FEAR…)
• WE WILL REACH THEM THROUGH _________ (CHANNEL, SPECIALTY, RETAIL, PHARMACIES…)
• BUT WE CAN ALSO ATTACK LARGER MARKET OF _________ (NEXT USER TYPE)
• OUR PRODUCT/SERVICE WILL BE PAID FOR BY _________ BECAUSE THEY VALUE _________ (UNIQUE
QUALITY,
© ZEN CHU 2010
36. THANK YOU VIT + MGH!
SEE ONE - DO ONE - TEACH ONE
APPLY HACKING PRINCIPLES
TO WHAT YOU OBSERVE
TO REMAKE THE FUTURE
HackingMedicine.MIT.edu
Twitter: #HackingMedicine @hackmedMIT
AboutMe.com/ZenVen
38. CLINICAL INNOVATION
CRITICAL SUCCESS
• DESIRE TO HELP PATIENTS
• RIGOROUS ANALYSIS + DATA
• FOCUSED PLAN TO EARLY PROOF
• CREATIVE TEAM
• ADAPT TO NEW DATA
• EVIDENCE-BASED
• SUSTAINABLE MODEL FOR PRODUCT/
SERVICE
© ZEN CHU 2010
39. INNOVATION RULES
• MINIMIZE TIME TO DEMONSTRATION
• BUILD SMALLEST POSSIBLE TEAM
• DEVELOP ONLY THE BARE MINIMUM
• PROVE ONE IDEA / VARIABLE AT A TIME
• ITERATE FREQUENTLY BEFORE MANUFACTURING
CONTROLS REQUIRED
• NEVER DEVELOP WHAT CAN BE BOUGHT
• INSIST ON HIGHEST QUALITY WORKMANSHIP FOR
FINAL PRODUCT
EMPHASIS ON SPEED & PROOF
© ZEN CHU 2010
40. BUILD TEAM TO EXECUTE
s e Market Risk
e r Physician & Patient Adoption
Reimbursement
e v
R n
Packaged Solutions
in Regulatory Risk t io
Value
n c u
la Safety & Efficacy
x e
) P E
1 Management Risk m
e a
Technology Risk )
T
2
Time
© ZEN CHU 2010
41. TIME IS LIFE
ACCELERANT DECCELERANT
REGULATORY Device 510(k) New materials & claims
Euro CE Literature Claims Unclear endpoints
Predictive animal models
CLINICAL Existing human data Non-superiority
Reproducible published studies Entrenched behavior
Acute episodic symptoms Chronic disease endpoints
REIMBURSEMENT Existing Codes DRGs Cost-Benefit Studies
Existing insurer coverage policies New codes required
Private-pay, consumer
MARKET Reduce skills needed Capital equipment purchase
Physician buying power No physician benefit
Unambiguous diagnostic
SALES Focused physician popul. Learning curves
Existing distribution Entrenched behavior
© ZEN CHU 2010
42. INCREMENTAL vs BREAKTHROUGH
Plenty of Incremental Value, BUT Different Strategy
METRIC INCREMENTAL BREAKTHROUGH
Funding $$ $$$$$$
Market Size Varies depending on funding >$100MM
needed No current therapies
Time Needed Shorter Longer
Adoption & Exit Match opportunity to strategy Regulatory path dependent
Value @ Exit Less More
Major Risks Window of opportunity Technical/Clinical unknowns
Execution quality & critical path Market adoption hurdles
Competition Reimbursement
Success Factors Focused execution Patents, Franchise Value
Management experience Market adoption, Std of Care
Manufacturing economics Investor expectations
Patent Protection Less More
Competition More Less
© ZEN CHU 2010